Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanubrutinib and Rituximab Followed by R-DHAOx (Rituximab, Dexamethasone, Cytarabine and Oxaliplatin) Regimen Then Maintenance With Zanubrutinib for Newly-Diagnosed Mantle Cell Lymphoma (MCL): a Single Arm, Open Label, Multi-center Phase II Study

X
Trial Profile

Zanubrutinib and Rituximab Followed by R-DHAOx (Rituximab, Dexamethasone, Cytarabine and Oxaliplatin) Regimen Then Maintenance With Zanubrutinib for Newly-Diagnosed Mantle Cell Lymphoma (MCL): a Single Arm, Open Label, Multi-center Phase II Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Dexamethasone (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary) ; Zanubrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2024 Status changed from recruiting to active, no longer recruiting, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results (n=42, data cut-off: Jan 2024) assessing safety and efficacy of frontline treatment with zanubrutinib plus rituximab followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL), presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 13 Dec 2022 Results (n=17; From Oct 2020 to Apr 2022) assessing the efficacy and toxicity of zanubrutinib and rituximab (ZR) combination followed by short course cytarabine-based chemotherapy, then maintenance with zanubrutinib monotherapy as frontline therapy in newly-diagnosed MCL patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top